CRSP Naimish Patel sells $141K worth of shares
May 31, 2025, 4:35 AM
0.00%
What does CRSP do
CRISPR Therapeutics AG, headquartered in Zug, develops gene-based medicines for serious diseases using its CRISPR/Cas9 platform and went public on October 19, 2016. The company focuses on gene editing to treat genetically-defined diseases and enhance cellular therapies.
Naimish Patel sold 3,932 shares of CRSP on 29 May at $35.94 per share, worth a total of $141K. They now own 6,068 CRSP shares, or a 39% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.